Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: Eur J Cancer. 2022 Feb 24;165:81–96. doi: 10.1016/j.ejca.2022.01.002

Figure 4.

Figure 4.

T cells, but not macrophages, are required for anti-tumor activity of RNLS inhibition. (A) Treatment of RNLS-KO mice bearing B16F10 tumors with control IgG results in tumor rejection (grey curve, N=5 mice). This effect is abrogated with anti-CD3 (yellow curve, N=5 mice). (B) Tumors harvested from these mice treated with anti-CD3 have lower CD4 and CD8 cell content, as expected. (C) Macrophage specific RNLS-KO (grey curve) is insufficient to significantly impact tumor growth compared to global RNLS-KO in the host (orange curve), N=5 mice per cohort.